The IBD SmartSelect Composite Rating for Insulet increased from 89 to 96 Friday.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The new score tells you the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Insulet is currently forming a consolidation, with a 329.33 buy point. Look for the stock to break out in volume at least 40% above average.
The stock earns a 99 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 99% of all stocks.
Its Accumulation/Distribution Rating of C shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
The company posted 113% earnings growth for Q2. That marks two straight quarters of rising EPS performance. Sales growth climbed 33%, up from 29% in the prior report. That marks two consecutive reports with rising growth.
Insulet earns the No. 1 rank among its peers in the Medical-Products industry group. TransMedics Group and ResMed are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
